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Abstract Progressive multifocal leukoencephalopathy is
a fatal viral-induced demyelinating disease that was once
rare but has become more prevalent today. Over the past
decades, much has been learned about the disease from
molecular study of the etiological agent of the disease, JC
virus. Recently, promyelocytic leukemia nuclear bodies
(PML-NBs), punctuate structures for important nuclear
functions in eukaryotic cells, were identiﬁed as an intra-
nuclear target of JC virus infection. Neuropathologically,
JC virus-infected glial cells display diffuse amphophilic
viral inclusions by hematoxylin–eosin staining (full inclu-
sions), a diagnostic hallmark of this disease. Recent results
using immunohistochemistry, however, revealed the pres-
ence of punctate viral inclusions preferentially located
along the inner nuclear periphery (dot-shaped inclusions).
Dot-shaped inclusions reﬂect the accumulation of viral
progeny at PML-NBs, which may be disrupted after viral
replication. Structural changes to PML-NBs have been
reported for a variety of human diseases, including cancers
and neurodegenerative disorders. Thus, PML-NBs may
provide clues to the further pathogenesis of JC virus-
induced demyelinating disease. Here, we review what we
have learned since the disease entity establishment,
including a look at recent progress in understanding the
relationship between JC virus, etiology and PML-NBs.
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Progressive multifocal leukoencephalopathy
History
Progressive multifocal leukoencephalopathy is a distinct
neurologic entity established in 1958 [5]. Two cases of
chronic lymphatic leukemia and one case of Hodgkin’s
lymphoma were described as having similar clinical out-
comes and sharing a characteristic neuropathology among
postmortem brains. Uniquely, a mixture of small and larger
demyelinating lesions was disseminated in the white matter
and to a lesser degree, also in the gray matter. The small
demyelinating lesions appeared to merge to form larger
ones, an arrangement that was distinct from other demyelin-
ating diseases known at that time. The fusion of multifocal
demyelinating lesions was regarded as a progressive process
and thus, the disease was named progressive multifocal
leukoencephalopathy (Fig. 1a).
The diagnostic hallmark of progressive multifocal
leukoencephalopathy is the presence of oligodendro-
cytes with enlarged nuclei containing intranuclear
amphophilic inclusions. The presence of abnormally
bizarre astrocytes has been also described. A link to
viral infection was suggested [19] and two independent
groups subsequently revealed the presence of polyoma-
like virions in round or ﬁlamentous forms by electron
microscopy [121, 150]. Isolation of the virus was dif-
ﬁcult but primary human fetal glia cells were eventually
identiﬁed as the ﬁrst cell culture system that could
support viral propagation. Human polyomavirus isolated
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the patient, Mr. John Cunningham [98]. Progressive
multifocal leukoencephalopathy was rare in those days,
and regarded as a ‘‘slow virus infection’’ of the central
nervous system, similar to scrapie, Kuru, and Creutzfeldt-
Jakob disease.
Fig. 1 Neuropathology of progressive multifocal leukoencephalopa-
thy. a Characteristic demyelinating patterns, in which small well-
demarcated lesions fuse to form larger lesions [Kluver-Barrera (KB)
staining, bar 1.0 mm]. b Broad myelin pallor in the white matter (KB
staining, bar 1.0 mm). c The same section shown in a. Glial cells
harboring amphophilic inclusions in the enlarged nuclei (arrowheads)
usually seen at the periphery of well-demarcated demyelinating
lesions (HE staining, bar 100 lm). d The same section as in b. Glial
cells with enlarged nuclei broadly scattered in the myelin pallor
(Bodian staining, bar 100 lm). e Small and condensed nuclei of
oligodendroglia surrounding cortex neurons. f Glial cells, potentially
JC virus-infected oligodendroglias, display enlarged but clear nuclei
without amphophilic inclusions. Dot-shaped structures (arrows) are
detected and resemble dot-shaped JC viral inclusions shown in j and
k. g, h Typical cells with intranuclear JC viral inclusions seen in the
myelin pallor (g) and at the periphery of well-demarcated demyelin-
ation (h)( e–h HE staining, bars 20 lm). i Immunohistochemistry
(IHC) to detect the promyelocytic leukemia (PML) protein. Punctate
PML distribution indicating the presence of PML-NBs. j, k Viral
genomic DNA and capsid proteins VP2/VP3 are detected in punctate
patterns (dot-shaped inclusions) by in situ hybridization (j) and IHC
(k), respectively. l JC viral capsid proteins, by IHC, are detected
throughout the nucleoplasm (full inclusions)( i–l bars 20 lm)
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123Clinical aspects observed over the past three decades
Progressive multifocal leukoencephalopathy develops in
patients with impaired immunity. The number of reported
cases of this previously rare disease has signiﬁcantly
increased since the 1980s due to the pandemic of acquired
immunodeﬁciency syndrome (AIDS). In the south of
Florida in the United States, for example, there was a 12-
fold increase in the frequency of diagnosis in 1990–1994
when compared with 1980–1984 [8]. Introduction of highly
active antiretroviral therapy (HAART), initiated in France
in 1996, has signiﬁcantly decreased the morbidity and
mortality of AIDS [56]; however, progressive multifocal
leukoencephalopathy remains a major AIDS complication
resulting in death [52]. Paradoxically, some patients
develop a deterioration associated with HAART treatment
known as immune reconstitution inﬂammatory syndrome
(IRIS). IRIS can result from reconstitution of the immune
system to recognize pathogens/antigens, and can be
accompanied by toxoplasmosis, cryptococcosis, and tubercu-
losis, as well as progressive multifocal leukoencephalopathy
[21, 51].
In non-AIDS patients, advancements in therapy of
underlying diseases and the increasing use of immuno-
modulatory drugs have markedly changed the clinical
background. Among cases associated with lymphoprolifer-
ative disorders, Hodgkin’s disease was the most frequently
reported underlying disease from 1958 to 1989; in contrast,
from 1990 to 2004, more reports linked the disease to B cell
chronic lymphocytic leukemia and non-Hodgkin’s lym-
phomas[45].Thismaybeinpartbecauseforthelattercases,
an increasing number of patients undergo high-dose che-
motherapywith hematopoieticstem celltransplantation[48,
67] or treatment with purine analogs such as ﬂudarabine
widely used since 1997 [45]. Transplant recipients of solid
organs, including kidneys, livers, hearts, or lungs, can also
develop demyelination, likely due to immunosuppressive
treatments used to prevent graft rejection [120]. The disease
can also develop in persons with rheumatic diseases related
or unrelated to immunosuppressive drug treatment; indeed,
systemic lupus erythematosus is one of the most common
underlying diseases [15, 17, 87, 95]. In 2005, development
of progressive multifocal leukoencephalopathy was repor-
ted with the use of natalizumab, a monoclonal antibody that
blocks inﬂammatory cell entry into the brain and is used for
multiple sclerosis and Crohn’s disease [70, 79, 135, 148].
Children with congenital immunodeﬁciency disorders [2]
and the elderly (in association with age-related immuno-
suppression) are also at risk. Thus, progressive multifocal
leukoencephalopathy is now relatively common and can
develop in association with a large number of different
diseases, treatments, and conditions that lead to immuno-
deﬁciency.
A diagnosis of progressive multifocal leukoencepha-
lopathy can be indicated by radiological imaging, but
detection of JC virus is essential for a deﬁnitive diagnosis.
JC viral DNA can be detected in the cerebrospinal ﬂuid by
polymerase chain reaction (PCR), but negative results do
not completely rule out the possibility. For example, PCR
results may be negative for HAART-treated AIDS patients,
due to clearance of the viral DNA associated with
improved immune responses [16, 46]. Therefore, patho-
logical examination of a biopsy or autopsy sample may be
required for a ﬁnal diagnosis. The clinical prognosis for
progressive multifocal leukoencephalopathy is usually
poor, with most cases resulting in death within 6 months,
although prolonged survival has sometimes been observed
[7, 8].
Neuropathology
Neuropathology of progressive multifocal leukoencepha-
lopathy now shows histological diversity, likely associated
with the expanded clinical spectrum of underlying diseases.
As described earlier, the originally identiﬁed neuropathol-
ogy was a typical arrangement of multiple well-demarcated
demyelinating lesions, preferentially seen in the cerebral
subcortical white matter [5] (Fig. 1a). However, for some
recent cases, apparent cortical demyelination has been
reported [11, 86, 127, 140]. The frontal lobes and parieto-
occipital regions are most commonly affected, but demy-
elination may be also observed in deep gray structures,
the cerebellum, the brainstem, and even in the spinal cord
[9, 61, 62, 115].
The degree of histologically detected demyelination and
of inﬂammation is also variable. Some cases display
myelin pallor (Fig. 1b), whereas others show marked
degeneration associated with axonal damage and the
appearance of numerous foamy macrophages harboring
phagocytolytic lipids or myelin debris. Such lesions are
regarded as ‘‘burnt out,’’ and are often observed in cases
associated with AIDS [52, 76]. A broad distribution of
burnt out lesions may imply prolonged survival concurrent
with advanced treatment [52]. The inﬂammatory response
is usually poor; however, in cases of IRIS, severe inﬂam-
mation may be present, including marked intraparenchymal
and perivascular inﬁltration by macrophages and T lym-
phocytes [51, 85, 136].
The etiology of progressive multifocal leukoencepha-
lopathy is JC virus lytic infection leading to the destruction
of myelin sheaths. Therefore, detection of glial cells har-
boring JC virus inclusions is essential for pathological
diagnosis. The characteristic cells are usually seen at the
periphery of the demyelinating lesions, if the lesions are
well demarcated (Fig. 1c). In contrast, if myelin pallor is
broadly dispersed, the affected cells also tend to be
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inclusions appear as amphophilic material dispersed
throughout the nucleoplasm (full inclusions), by hema-
toxylin–eosin (HE) staining. However, the presence of
numerous cells is also noted, which have a clearer nucle-
oplasm and marginated chromatin but lacking amphophilic
material, despite nuclear enlargement (Fig. 1e–h). By
immunohistochemistry, some of these cells display a
distinct punctate distribution of promyelocytic leukemia
(PML) protein, indicating the appearance of promyelocytic
leukemia nuclear bodies (PML-NBs; note that for clarity,
‘‘PML’’ refers herein only to promyelocytic leukemia or
PML protein, and not to the disease progressive multifocal
leukoencephalopathy) (Fig. 1i). Both the JC viral DNA
genome and viral capsid proteins show punctate signals by
in situ hybridization and immunohistochemistry, respec-
tively (dot-shaped inclusions) (Fig. 1j, k). Because PML
protein and JC viral capsid proteins co-localize [117, 118]
(Fig. 7), PML-NBs are likely the sites of JC viral replica-
tion. Dot-shaped inclusions are indicative of an earlier
stage of viral infection, prior to the stage at which full
inclusions would be observed (Fig. 1j–l).
By electron microscopy, JC virions are round or ﬁla-
mentous structures, approximately 35–40 nm in size.
Although the intranuclear distributions of viruses are var-
iable, many cells contain more viruses at the periphery than
in center of the nucleus. Occasionally, round virions dis-
play a perfect alignment pattern, called crystalloid arrays
(Fig. 2). This alignment pattern indicates that viral spread
is associated with speciﬁc intranuclear structures, rather
than being the result of viruses freely ﬂoating in the
nucleoplasm. In 1980, Mazlo and Tariska [84] investigated
the ﬁrst phase of viral replication using electron micros-
copy and reported that viral progeny always appear in
the vicinity of the inner nuclear membrane after nuclear
enlargement of infected oligodendrocytes. Today, we
better understand the development of intranuclear viral
inclusions at a molecular level; nevertheless, even 30 years
later these new ﬁndings are consistent with earlier results
based on extensive ultrastructural studies.
The JC virus biology and molecular pathogenesis
The human polyomavirus JC genome
JC virus has a circular double-stranded DNA genome. The
complete sequence was ﬁrst determined for the Mad-1
strain (5,130 bp) [41]. The ﬁrst Japanese strain, Tokyo-1
(5,128 bp) was isolated [90], and we determined its com-
plete sequence [116]. JC virus shares approximately 70%
DNA sequence similarity with SV40 and BK virus, and
displays a similar tripartite genome organization with early
and late coding regions and a regulatory region. The early
coding region encodes multifunctional regulatory proteins,
large T antigen and its splicing variants (t, T0
135,T 0
136, and
T0
165)[ 134]. The late region encodes three capsid proteins,
VP1, VP2, and VP3, and a small regulatory protein called
agnoprotein.
The JC viral regulatory sequence is located between the
early and late coding regions, and the promoter-enhancer
elements function bidirectionally. The regulatory sequence
displays marked diversity, but the sequences can be
roughly divided into two groups, ‘‘archetype’’ and ‘‘neu-
rotropic type’’. Viruses isolated from the urine of healthy
individuals have consistently been found to contain a
characteristic regulatory sequence known as the archetype,
which is composed of ﬁve segments: 25-, 23-, 55-, 66-, 18-
bp sequences (Fig. 3). In contrast, viruses isolated from
demyelinating brains display divergent sequences desig-
nated as the ‘‘neurotropic type’’ (also referred to as the
‘‘PML-type’’ where ‘‘PML’’ means progressive multifocal
leukoencephalopathy). The neurotropic type regulatory
sequences appear to have arisen from the archetype via
deletion and duplication. For example, in the Mad-1
sequence, the 23- and 66-bp segments are deleted, and the
25-, 55-, and 18-bp segments are duplicated, resulting in
98-bp tandem repeats. In the Tokyo-1 sequence, the 66-bp
portion is largely deleted, most 55- and 18-bp segments are
duplicated, with a unique 17-bp sequence insertion [83].
Sequence rearrangement from the archetype to the neuro-
tropic type may increase restricted tissue tropism or
Fig. 2 Electron micrograph of JC virions. JC virions, uniform in both
size and shape display perfect alignment patterns called crystalloid
arrays (Bar 1 lm). Courtesy of Drs. Shigeki Takeda and Hitoshi
Takahashi
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123virulence, thus affecting the overall of pathogenic potential
of the virus [22]. However, it is also argued that sequence
rearrangement does not change the JC virus biology [124].
The so-called ‘‘archetype hypothesis’’ will be described
further below.
The archetype hypothesis
Early interest focused on the idea of ‘‘slow virus infection’’
and the question was frequently raised, how does JC virus
persist asymptomatically but in some cases, cause oppor-
tunistic demyelinating disease? JC virus is ubiquitous in
human populations and approximately 50–80% of adults
present antibodies against the virus [72, 97]. Although
seroprevalence continues to increase until the seventh
decade of life, most individuals are thought to already have
asymptomatic infections by early childhood. Primary
infections may occur via respiratory inhalation [109, 113]
or through consumption of contaminated food or beverages
[12–14]. The viruses are presumably latent or persistent in
lymphoid organs such as the spleen or tonsils, as well as
bone marrow, and circulate in association with peripheral
lymphocytes, monocytes, or cell-free plasma [32, 33, 43,
57, 88, 133]. A small amount of virus seems to replicate in
the kidney and the virus is occasionally excreted in the
urine. Circulating viruses may reach the brain and if host
immunity is compromised, the virus can cause progressive
multifocal leukoencephalopathy.
In 1990, in what is arguably one of the most important
and interesting studies in the ﬁeld, the presence of the so-
called archetypal viruses was advocated [147]. Archetypal
viruses are frequently excreted in the urine of healthy
individuals [69, 146, 147] and detected in urban sewage
[14]. Thus, it seems to be the archetype that circulates
in the human population. It has been proposed that
subsequent to a primary infection, the archetype remains
quiescent in the kidneys or other organs with occasional
excretion to the urine. Some time later, the virus may
transform to the neurotropic type via sequence rear-
rangement (in particular, deletion and duplication; see
above). Neurotropic type viruses acquire neurovirulence
and thus can cause progressive multifocal leukoencepha-
lopathy (Fig. 4a).
Subsequent to the promotion of the archetype idea, how
and where the viruses transform from the archetype to the
neurotropic type became a subject of debate. If the virus is
transmitted via respiratory inhalation, then it would stand
to reason that the archetype would be detected in tonsilar
tissues, an initial site of infection. In one report, however,
viral sequences from such samples were identiﬁed as
mostly of the neurotropic type [88], although archetypal
sequences were detected in another study [63]. JC virus
may be transmitted by consumption of contaminated food
or beverages [12–14] and consistent with this, JC viral
sequences are frequently detectable in the human gastro-
intestinal (GI) tract [77, 106, 107]. However, according to
one study, viral sequences detected in the GI tract were
identiﬁed as belonging to the Mad-1-like neurotropic type
[77]. JC virus may also circulate in the body in association
with peripheral blood lymphocytes (PBLs), where
sequence arrangement may occur. One study reports that
the viruses in PBLs were mostly of the neurotropic type
[31], and the presence of both archetype and neurotropic
types was reported in another study [6]. Bone marrow has
also been suggested as the site of transformation, as neu-
rotropic type virus has been detected there as well [130].
Making the story yet more confusing, the presence of JC
viral DNA has repeatedly been detected in postmortem
brain tissue taken from patients who died from non-neu-
rologic diseases [29, 36, 99, 141]. Unexpectedly, these
viruses contain the rearranged, neurotropic type sequences
and thus, the possibility arises that the brain is also a site of
latency [29, 99, 141]. Repeated detection of neurotropic
viruses in multiple organs of carrier individuals stimulated
arguments against the archetype hypothesis. Importantly,
pediatric patients with congenital immunosuppression dis-
play progressive multifocal leukoencephalopathy in which
both archetype and neurotropic type viruses are present in
different tissues. These data have been interpreted to mean
that in some patients, demyelinating disease may develop
after a primary infection rather than requiring a latency
period [93, 94]. The archetype hypothesis has been widely
accepted and indeed, the disease may occur by transfor-
mation from the archetype to neurotropic type. However, at
least one alternative possibility remains, i.e. that neuro-
tropic type viruses also circulate in normal human
populations and moreover, may cause demyelinating dis-
ease upon primary infection (Fig. 4b).
Fig. 3 JC viral regulatory sequences. The viral regulatory sequences
are divergent and divided into two groups, the ‘‘archetype’’ and
‘‘neurotropic type.’’ The archetype sequence consists of ﬁve sub-
sequences, 25-, 23-, 55-, 66-, and 18-bp. The sequence of neurotropic
types, such as Mad-1 and Tokyo-1, may be derived from the
archetypal sequence via deletion and duplication. For details, refer to
Yogo et al. [147]
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Today, we know that JC virus infection is not speciﬁc
to oligodendrocytes, as viral DNA or proteins have
been repeatedly detected in multiple tissues. However,
the disease-state outcome of infection, progressive multi-
focal leukoencephalopathy, selectively occurs in human
oligodendroglias. Why JC virus establishes its most efﬁ-
cient lytic infection in this speciﬁc cell type and not others
remains largely an open question.
The life cycle of polyomaviruses is comprised of early
and late events. During early events, viral infection is ini-
tiated by attachment to a cell surface receptor, followed by
trafﬁcking from the cell membrane toward the nucleus.
Next, T antigens are synthesized, and they assist replication
of viral genomic DNAs in the nucleus. During late events,
the viral capsid proteins VP1, VP2, and VP3 are synthe-
sized in the cytoplasm, and they localize to the nucleus for
production of viral progeny. Finally, viral progeny are
released from the cells, at which time they can go onto
infect additional host cells (Fig. 5a). Cellular susceptibility
for lytic infection can be determined at any stage in the
lytic cycle.
JC virus can bind to receptors present on a variety of cell
types, but progeny production does not necessarily occur in
all cell types. Viral entry is mediated by a ubiquitous
Fig. 4 The archetype hypothesis. a Archetypal viruses are frequently
detected in the urine of healthy individuals, whereas neurotropic types
are detected in the brains with progressive multifocal leukoenceph-
alopathy. Thus, the archetypal viruses, which are ubiquitous in the
human population, may occasionally transform into the neurotropic
type, resulting in development of opportunistic demyelinating disease.
b Detection of the archetype and neurotropic type in multiple tissues
of carrier individuals has raised questions about the archetype
hypothesis. See text for a detailed discussion
Fig. 5 What determines JC virus neurotropism? a The viral life cycle
begins with binding to cell surface receptors and is completed by the
release of progeny from the host cell. Cellular susceptibility, for
efﬁcient production of viral progeny, can be regulated at any stage in
the lytic cycle. b Although JC virus is now known to infect a variety
of cells, the most efﬁcient progeny production appears to occur in
oligodendroglias, a phenomenon thought to be determined by
multiple nuclear factors
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sialic acids, which associates with the serotonergic receptor
5HT2A on human glial cells [35, 81]. However, even when
the virus attaches to cell surface receptors, or penetrates
and reaches the nucleus, these events may not always lead
to completion of the viral lytic cycle. The results of in vitro
experiments demonstrated that JC virus entry into nuclei
was observed for 15 different types of cell lines, but among
them, virus replication occurred exclusively in human
neuroblastoma cells [126]. The data indicate that the
presence of cell surface receptors is essential but does not
speciﬁcally determine cellular susceptibility for efﬁcient
lytic infection [34, 139] (Fig. 5b).
The 98-bp tandem repeats in the regulatory sequence of
Mad-1 were found to be a transcriptional regulatory ele-
ment with enhancer-like activity in human glial cells [65].
Since then, the results of many studies have supported the
idea that restricted lytic infection by JC virus in human
brain tissue depends on the presence of nuclear factors that
are predominantly expressed in glial cells. The rearranged
sequence of the regulatory regions markedly affects the
levels of viral transcription and replication, as they encode
binding sites for nuclear proteins that regulate viral DNA
replication or transcriptional activity. The sequences
include the TATA box, and binding sites for nuclear
transactivators, including Sp1, YB1, sup2, NF-jB, Pura,
Tst-1, c-Jun, and NF-1 (reviewed in [102]). Thus, efﬁcient
lytic infection in speciﬁc cells seems to be dependent on
multiple nuclear factors that selectively bind to the rear-
ranged regulatory sequence.
Interestingly, recent studies have revealed that JC virus
also infects neurons in cerebellar granule layers and even
pyramidal neurons in the cerebral cortex. In the cerebel-
lum, lytic infection of granule cells was proposed as JCV
granule cell neuronopathy, and in the cerebral cortex,
fulminant JC virus encephalopathy [73, 143, 144]. These
data suggest that efﬁcient lytic infection proceeds even in
neuronal cells, a process less well understood than lytic
infection in glial cells.
PML-NBs as an intranuclear target for JC virus
infection
Since establishment of a eukaryotic expression system to
generate virus-like particles (VLPs) [119], we have been
studying the molecular mechanisms underlying how JC
virus develops intranuclear inclusions. The JC virus capsid
would be composed of VP1, VP2, and VP3, likely in a
speciﬁc ratio as in SV40 [80]. Proportional expression of
the capsid proteins is in part regulated by alternative
splicing, and at least four species of late RNAs are pro-
duced (M1–M4) [116]. Of these, it is M1 that encodes VP2/
VP3 and M2 that encodes VP1, which is downstream of
agnoprotein (Fig. 6) (note that because the complete amino
acid sequence of VP3 is identical to the C-terminal two-
thirds of VP2, we refer to them collectively as VP2/VP3).
Nuclear proteins typically contain nuclear localization
signals (NLSs), most commonly a stretch of basic amino
acids such as K (lysine) and R (arginine). JC virus VP1
is inefﬁcient in nuclear transport, which is attributable
to what is presumably a weak NLS in its N-terminal
sequence, MAPTKRKGERKD. This sequence has the
properties of an NLS; namely, basic amino acids (K
5R
6K
7
and R
10K
11) ﬂank the intervening residues GE (super-
scripts indicate the positions of residues in an amino acid
sequence). This can be compared with SV40 VP1, which
includes the sequence MAPTKRKGSCPGAAPKKPKE
(including K
5R
6K
7 and K
16K
17,K
19), which functions as
an efﬁcient, bipartite NLS [58]. It stands to reason, then,
that with its functionally weak NLS, JC virus VP1 is dis-
tributed in both the cytoplasm and the nucleus, whereas
with its efﬁcient NLS, SV40 VP1 is exclusively localized
to the nucleus. Exclusive nuclear localization of JC virus
VP1 can be achieved upon co-expression with VP2/VP3,
which contains two clusters of basic amino acids in
the C-terminal region, GPNKKKRRK (cluster 1) and
KRRSRSSRS (cluster 2). These sequences compensate for
the inefﬁcient nuclear targeting of VP1.
Interestingly, co-transported capsid proteins were found
to accumulate at dot-shaped subnuclear domains prefer-
entially detected at the nuclear periphery; that is, at
PML-NBs. Confocal microscopic analysis has clearly
demonstrated co-localization of VP1 with PML protein, a
major component of PML-NBs. Co-localization in a dot-
shaped distribution pattern was observed both in human
brain tissues with progressive multifocal leukoencepha-
lopathy and in COS-7 cells producing VLPs. In the nuclei,
major and minor capsid proteins were found to stretch their
intranuclear distributions alongnuclear matrix-like structures
(Fig. 7a, b).
Fig. 6 Structures of JC virus late RNAs. Expression of major capsid
protein VP1 and minor capsid proteins VP2/VP3 is kept roughly
proportional by alternative splicing. VP1 is encoded on the M2 RNA,
and VP2/VP3 on M1, downstream of the agnoprotein. Diagram based
on Shishido-Hara et al. [116] (used with permission)
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lation in COS-7 cells, we have revealed that in the presence
of VP2/VP3, colloidal gold particles representing the VP1
epitopes were clustered along the inner nuclear periphery,
where numerous VLPs with both round and ﬁlamentous
structures were also observed. The data are consistent with
whathas been seen forJC virus-infectedglial cellsinhuman
brain (Fig. 8). Altogether, it appears that major and minor
capsid proteins move cooperatively from the cytoplasm to
the nucleus and then accumulate in PML-NBs, where they
are assembled into progeny virions (Fig. 9).
What is the mechanism of JC virus-mediated cell
death?
The mechanisms of JC virus-mediated cell death remain
largely unclear. JC virus-infected cells may undergo
apoptosis [108, 145]. However, this is in contrast with
another report, in which the authors suggest that JC virus-
mediated cell death is a non-apoptotic, necrotic mode of
death in progenitor-derived astrocyte cell culture [114].
A recent study also demonstrated higher expression of the
anti-apoptotic protein survivin, and the authors claimed
that viral-infected cells are anti-apoptotic, allowing for
completion of the viral lytic cycle [100].
During development of full viral inclusions, PML-NBs
may go on to disrupted [117, 118], and our current thinking
is that disruption or even dysfunction of PML-NBs may
induce JC virus-mediated cell death. Indeed, disruption or
dysfunction of PML-NBs is associated with a variety of
human diseases, including cancers, neurodegenerative
disorders, and viral infections, as described below.
PML-NBs and human diseases
PML-NBs, also known as PML oncogenic domains or
nuclear domain 10 (ND10), are dynamic, macromolecular,
dot-shaped structures that are ubiquitously present in
eukaryotic cells (recent reviews in [10, 20, 30, 103]).
Fig. 7 JC viral capsid proteins
accumulate at PML-NBs in
human brain tissue and COS-7
cells. JC virus capsid protein
VP1 co-localizes in dots with
the PML protein, a major
component of PML-NBs. This
was observed both in a human
brain with progressive
multifocal leukoencephalopathy
(a) and in COS-7 cells
producing VLPs (b top). Both
VP1 and VP2/VP3 were
distributed within the nucleus,
associated with matrix-like
structures (b bottom). a, b Top
are from Shishido-Hara et al.
[118] (used with permission)
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cell cycle regulation, DNA replication, repair, transcrip-
tion, apoptosis, and senescence. PML-NBs vary both in
size and in number, depending on the cell cycle phase and
differentiation state of the cell, and in response to cellular
stress [30, 132]. In cells cultured in vitro, PML-NBs are
generally few and smallest in G0, and more numerous and
larger when in S phase. PML-NBs are re-established in G1
after mitosis. PML-NBs are structurally and functionally
heterogeneous, and nuclear proteins including p53, CBP/
p300, Daxx, BLM, Pin1, HDAC7, and pRB trafﬁc in and
out, depending on both normal and pathological conditions.
PML protein expression is frequently up-regulated in
activated cells [44].
The pathogenic signiﬁcance of PML-NBs was ﬁrst
indicated in acute promyelocytic leukemia, wherein the
PML gene is fused to the retinoic acid receptor a (RARa)
gene due to t(15;17) chromosomal translocation, resulting
in disruption of PML-NBs [23, 47, 60]. Subsequent to this
ﬁnding, the PML protein and PML-NBs were studied
extensively in relation to tumorigenesis, both in basic
research studies and in the clinic. PML-NBs are sites of
tumor suppression, where PML protein and p53 function
cooperatively [50, 111]. PML protein expression is reduced
or abolished in human cancers of various histologic origins,
including prostate, colon, breast, lung, lymphomas, CNS
tumors, and germ cell tumors [53]. Interestingly, PML-NBs
interact with particularly gene-rich and transcriptionally
active regions of chromatin, including the TP53 locus that
encodes p53 [125]. Therefore, the PML protein as well as
PML-NBs has signiﬁcant functions for tumor suppression,
especially as associated with p53. Thus, their dysfunction
or disruption likely relate to both oncogenesis and tumor
progression.
Polyglutamine diseases such as Huntington’s disease
and spinocerebellar ataxias are neurological diseases
characterized by genetic mutations of expanded CAG
repeats that encode polyglutamines (polyQ). The mutant
proteins with expanded polyQ tracts accumulate in the
nucleus and form neuronal intranuclear inclusions (NIIs).
NIIs are frequently associated with PML-NBs [128, 129].
The results of in vitro experiments show that the matrix-
associated PML-NB structures are disrupted by polyQ
mutant proteins [64, 123]. Thus, the presence of NIIs may
cause disordered nuclear functions, such as altered or
impaired transcription, as well as induce cell death or
degeneration of neuronal cells [42, 96]. Moreover, much
interest has been focused on understanding the role of
PML-NBs in protein storage and ubiquitin-mediated
Fig. 8 Electron micrographs of JC virions in human brain tissues and
of VLPs in COS-7 cells. a In human brain tissue with progressive
multifocal leukoencephalopathy, electron microscopy reveals clus-
tered native virions of both round and ﬁlamentous structures at the
inner nuclear periphery, indicative of PML-NBs. b Consistently, in
cultured cell lines producing VLPs, immunogold labeling VP1
epitopes is clustered at the nuclear periphery, where assembly of
VLPs of both round and ﬁlamentous structures is detected (Bar
1 lm). Both panels are from Shishido-Hara et al. [117] (used with
permission)
Fig. 9 Schematic illustration of late events in the JC virus life cycle.
VP1 may associate with VP2/VP3, and they are co-transported to the
nucleus. Complexes of VP1 and VP2/VP3 are assembled into progeny
virions at PML-NBs, and likely spread throughout the nucleoplasm,
along with matrix-like structures
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123degradation by proteasomes [59, 92]. A model was pro-
posed wherein PML-NBs scan the nucleus in search of
misfolded proteins and promote degradation of these errant
proteins via the proteasome. However, it is not yet clear if
the presence of NIIs is pernicious, coincidental, or bene-
ﬁcial for neuronal cells [71, 112, 122].
A variety of viruses target PML-NBs, including herpes
simplex virus type-1 (HSV-1), human cytomegalovirus
(HCMV), Epstein–Barr virus (EBV), papillomaviruses, and
polyomaviruses. These viruses may alter components of
PML-NBs, regulate expression and localization of PML
protein, and even disrupt PML-NB structure (recent review
in[131]).Forexample,HSV-1, HCMV, andEBValldisrupt
PML-NBs during early events of viral replication, whereas
human papillomavirus type 33 (HPV33) reorganizes PML-
NB components and utilizes them for efﬁcient capsid
assembly during late events [39, 40]. Expression of PML
proteinisup-regulatedafter treatmentwith interferon(IFN),
suggesting that PML-NBs would be an anti-viral structure
[38]. Recent data, however, also indicate that PML-NBs are
at least in part pro-viral, and facilitate latency in HSV-1 and
HCMV infection [110]. As we understand it today, pro-
gressive multifocal leukoencephalopathy is a JC virus-
induced demyelinating disorder of the nervous system, in
which PML-NBs are the targets for viral infection. How
PML-NBsareinvolvedinorutilizedforJCvirusinfectionis
the next issue that will be addressed (Fig. 10a).
Does JC virus induce brain tumors in humans?
Finally, we reconsider a long-lasting question asked since
the discovery of JC virus, Can JC virus induce brain tumors
in humans? This question has been raised many times, as
the virus-induced brain tumors in experimental animals,
and viral DNA or proteins were repeatedly detected in
human tumor tissue (reviewed in [66, 104, 142] and oth-
ers). In 1970s, it was shown that JC virus inoculated into
experimental animals can induce brain tumors [82, 137].
The JC virus Tokyo-1 strain was shown to induce medul-
loblastoma in hamsters [91]. Indeed, JC virus was highly
oncogenic and capable of inducing various types of brain
tumors in these animals, including glioblastomas, medul-
loblastomas, neuroblastomas, pineocytomas, and/or other
tumors of central nervous system. In 1999 and 2000,
transgenic mice were generated in which the early regions
of the archetype or neurotropic type are presented, and both
were capable of inducing medulloblastoma/primitive neu-
roectodermal tumor (PNET) and pituitary neoplasia [49,
75]. Thus, there is no doubt in that JC virus is oncogenic to
experimental animals.
Fromthelate1990stotheearly2000s,anumberofreports
described detection of JC virus, a viral DNA genome or
oncogenic T antigen, in human clinical samples. JC virus has
been detected in brain tumors of different histological types,
includingmedulloblastoma,astrocytoma,oligodendroglioma,
Fig. 10 Does JC virus induce brain tumors in humans? a PML-NBs
are the sites of multiple nuclear functions, and disruption or
dysfunction of PML-NBs can cause a variety of human diseases,
including leukemia and other cancers, as well as neurodegenerative
disorders. Many viruses target PML-NBs. b JC virus-induced brain
tumors are observed in experimental animals but whether or not this is
clinically true in humans remains at issue
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123oligoastrocytoma, anaplastic astrocytoma, anaplastic oligo-
dendroglioma,glioblastoma,ependymoma,andprimaryCNS
lymphoma [18, 24–27, 74, 105]. The virus has also been
detected in colorectal, gastric and esophageal cancers, and
even inlung cancers [1,28, 37, 77, 89,107, 149].However, it
is difﬁcult to know if the virus is causative for human tumors,
as JC virus is ubiquitously prevalent in the human population
and has been detected in multiple tissues, including the unaf-
fected brains, as described earlier. In addition, some groups
have reported discordant results suggesting that JC virus is
unlikely to be linked to oncogenesis in medulloblastoma or
PNET[54,68,138],andinoligodendrogliomaorastrocytoma
[55]. Thus, it is not yet clear if JC virus infection causes
malignant tumors in humans.
In progressive multifocal leukoencephalopathy, the glial
cells with enlarging nuclei seem markedly activated in their
cell cycle, with distinct expression of MIB-1 (Ki-67),
proliferating cell nuclear antigen (PCNA), cyclin A and
cyclin B1 [3, 4, 78]. The results of microarray analysis also
demonstrate enhanced transcription of the cyclin A and B1
genes [101]. Despite relatively high MIB-1 expression,
however, mitotic ﬁgures have not been observed. Thus, JC
virus likely ﬁrst activates host cells in their cell cycle,
which is presumably advantageous for viral progeny pro-
duction, but before completion, the cycle is dysregulated or
blocked. To address the persisting question if JC virus can
induce malignant tumors in humans, it might be useful to
clarify how cell fate is determined in infected cells and
separated into lytic infection versus malignant transfor-
mation. We expect that studies on PML-NBs might provide
interesting clues that could increase our understanding in
the future (Fig. 10b).
Conclusions
Neuropathology of progressive multifocal leukoencepha-
lopathy has diverged with the expanded clinical spectrum
of underlying diseases. Nevertheless, studies on JC virus
biology have advanced our understanding of this demye-
linating disorder. Nuclear viral inclusions in the form of
either full inclusions or dot-shaped inclusions are present in
the enlarged nuclei of glial cells, and PML-NBs have been
identiﬁed as an intranuclear target of JC virus infection.
We hope future studies on PML-NBs may provide clues as
to how fate is determined in JC virus-infected cells, as well
as insight into JC virus-mediated lytic infection or malig-
nant transformation.
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